Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
about
The Therapeutic Targets of miRNA in Hepatic Cancer Stem CellsLiver cancer stem cell markers: Progression and therapeutic implicationsIncreased Oxidative Stress as a Selective Anticancer TherapyA new prospect in cancer therapy: targeting cancer stem cells to eradicate cancerResearch progress and prospects of markers for liver cancer stem cellsCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionThe Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular CarcinomaInvolvement of inflammation and its related microRNAs in hepatocellular carcinomaStem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancerEstablishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cellsCD13 is a therapeutic target in human liver cancer stem cellsHsa-miR-520d induces hepatoma cells to form normal liver tissues via a stemness-mediated process.Hyaluronic acid-modified manganese-chelated dendrimer-entrapped gold nanoparticles for the targeted CT/MR dual-mode imaging of hepatocellular carcinoma.Stem cells in hepatocarcinogenesis: evidence from genomic dataIdentification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signalingCelecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell linesTumor-initiating cells are enriched in CD44(hi) population in murine salivary gland tumor.Role of liver stem cells in hepatocarcinogenesis.Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma.Clinical implications of cancer stem cell biology in hepatocellular carcinoma.Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells.Novel therapeutic strategies for targeting liver cancer stem cells.Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinomaIncreased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma.The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistanceDownregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the β-catenin pathway in hepatic oval cells.CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.Expression of the Transmembrane Glycoprotein CD44s Is Potentially an Independent Predictor of Recurrence in Hepatocellular Carcinoma.Coexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinomaInduction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinomaIdentification of cancer stem cell subpopulations of CD34(+) PLC/PRF/5 that result in three types of human liver carcinomas.PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferationTherapeutic application of stem cells in gastroenterology: an up-date.Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression
P2860
Q26749450-6FA439A5-F571-48AE-A861-D0467F3EC22CQ26751026-33158A4F-9D01-4555-BC84-65392ECA24DDQ26798210-B11DF0C6-06D1-4E70-B2E2-94FCA3448B93Q27022134-932E0EF0-9D14-4757-9C47-74170F8C0163Q27022262-B7BBDE7C-6A11-4187-A478-C8307803636DQ28066285-A76C35BA-95C4-4B82-B15D-32BE1A7E7D0DQ28071619-46E806A8-F040-4A2F-A34B-6DBA2004FCB7Q28079138-3975E8D3-B242-471E-B79E-701B6353DDFBQ28079205-107908A1-24DA-4EAA-92D7-B72436682D23Q28539620-657A2B39-FAAB-4C65-A700-D2329F133C4FQ30496324-0825C6FD-AAF4-4E4E-A4E6-9F708A716B13Q30567484-143A3F07-C088-4E64-B213-FDC41A712CC0Q31132171-040F7F8B-FEFE-4123-A534-4EE9F8189F9BQ33533408-8EF663F0-B6CC-4718-ADB3-CF42378A886CQ33588191-FA6595F6-A252-4D48-B3FC-ABFA1B9889B0Q33688897-2A7B7D4B-0D9B-4B21-B0C1-11F5DC6993BAQ33690881-006440BD-D6FE-4527-9C09-47F1F62B5505Q33729015-1F533684-BC70-4C4C-8317-149634CE4A9EQ33903701-15F5187D-8171-4FD6-8EED-8EDE292CBF4EQ33931154-782CFC19-BBD9-40B8-A47B-27899860A962Q33999375-E9E38C7C-603C-4C98-B0A9-C360EC3E56C8Q34259112-FFD53C4F-D4AC-4CE1-86C5-4792ADE04BCCQ34292958-4E41A055-AC15-4700-AF95-5BE78D51BAEBQ34357073-11B25A37-C12C-4BF4-A14E-ACB33D017BABQ34786517-AF06F091-7CE5-4BAE-9FF3-70A34FCA04F1Q34803710-B7D2905D-8D7F-416A-85DE-3EC969891D2EQ34940971-D27BCFAA-DD54-45DC-B674-D6631ACB3C03Q34984377-D4D9EA8A-C720-4020-A5C9-328CE07D1974Q35005633-C3BA9576-68BA-49DE-9AB7-C446A9F00CFAQ35045419-228B856F-14FC-46F3-BAF6-27ABAA3A4CD6Q35048411-E4D6EFE5-B0F4-4859-88FC-A064E8F765ECQ35085998-F458F672-656F-4D85-B51E-33931423F589Q35119166-51861F0A-EC7D-464C-BA23-706986C731D2Q35146510-65DD5440-6A4E-4A93-9A6C-7337BA69FBA8Q35234688-DD0DD5E3-663C-4253-930A-CC7570941123Q35323613-CB5290E9-FD90-4557-845C-FE18EBE97807Q35324465-EBD5D2DA-6D79-4BAD-9FCB-38F11611A7A4Q35404189-1E9195BD-DC06-4A0B-8F4C-DDB7149F017FQ35410105-899F7277-B67A-4E3B-83B9-A2D1100D422CQ35545627-DA7ACDC1-225F-474A-B905-923810C6AAC6
P2860
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@en
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@nl
type
label
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@en
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@nl
prefLabel
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@en
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@nl
P2093
P356
P1476
Cancer stem/progenitor cells a ...... n in hepatocellular carcinoma.
@en
P2093
Jianren Gu
Mingxia Yan
Xiangfang Hao
P304
P356
10.1002/IJC.24868
P577
2010-05-01T00:00:00Z